SCHEMBL5542006

SCHEMBL5542006

CCCC1Cc2cc(O)ccc2O1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SHBG P04278 1/20 0.48
HRH4 Q9H3N8 1/20 0.43
HRH3 Q9Y5N1 1/20 0.43
ESR1 P03372 2/20 0.42
ESR2 Q92731 2/20 0.42
DPP4 P27487 1/20 0.42
DRD3 P35462 2/20 0.41
MEN1 O00255 2/20 0.41
GLA P06280 2/20 0.41
KMT2A Q03164 2/20 0.41
GAA P10253 1/20 0.41
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41
NR1I2 O75469 1/20 0.41
GMNN O75496 1/20 0.41
USP2 O75604 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
TP53 P04637 1/20 0.41
CYP1A2 P05177 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5548100 0.91 SHBG (0.43) SHBGHRH4HRH3ESR1ESR2
SCHEMBL5536727 0.89 GRM2 (0.44) SHBGHRH4HRH3DRD3DRD2
SCHEMBL5537748 0.88 GRM2 (0.46) SHBGHRH4HRH3DRD3DRD2
SCHEMBL5543458 0.87 SHBG (0.44) SHBGDRD3KDM4EALDH1A1CYP3A4
SCHEMBL5536594 0.87 MEN1 (0.50) HRH4HRH3ESR1ESR2DPP4
SCHEMBL27876102 0.84 ESR1 (0.54) ESR1ESR2DRD3DRD2DRD4
SCHEMBL9628546 0.81 DRD3 (0.45) HRH4HRH3DPP4DRD3MEN1
SCHEMBL9627841 0.81 DRD3 (0.45) HRH4HRH3DPP4DRD3MEN1
SCHEMBL5541999 0.81 HRH3 (0.40) HRH4HRH3KDM4EFYN
SCHEMBL7798235 0.80 FFAR4 (0.52) ESR1ESR2DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 SHBG 3836/4885HRH4 426/4885HRH3 420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.